

## Performance Characteristics of Endoscopic Ultrasound in the Staging of Pancreatic Cancer: A Meta-Analysis

Haq Nawaz<sup>1</sup>, Chen Yi-Fan<sup>3</sup>, John Kloke<sup>2</sup>, Asif Khalid<sup>1</sup>,  
Kevin McGrath<sup>1</sup>, Douglas Landsittel<sup>2</sup>, Georgios I Papachristou<sup>1</sup>

<sup>1</sup>Division of Gastroenterology, Hepatology and Nutrition and <sup>2</sup>Institute for Clinical Research Education, University of Pittsburgh Medical Center; <sup>3</sup>Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA, USA

### ABSTRACT

**Context** The optimal approach to pre-operative imaging assessment of pancreatic cancer is unknown. **Objective** The aim of this meta-analysis was to assess accuracy and performance characteristics of EUS in determining nodal staging, vascular invasion, and prediction of resectability of pancreatic cancer. A secondary aim was to perform head to head comparison of performance characteristics between EUS and CT for nodal staging, vascular invasion and resectability. **Design** Data from EUS studies were pooled according to bivariate generalized random effects model. Pooled estimates for CT were obtained from studies which performed head to head comparison between EUS and CT. **Patients** Patients with pancreatic cancer undergoing pre-operative imaging assessment. **Intervention** EUS. **Main outcome measure** Pooled sensitivity, specificity, positive and negative predictive values of EUS for nodal staging, vascular invasion and resectability. **Results** Forty-nine studies were considered of which 29 met inclusion criteria with a total of 1,330 patients. Pooled summary estimates for EUS-nodal staging were 69% for sensitivity and 81% for specificity. For vascular invasion, sensitivity was 85% and specificity was 91%. The sensitivity and specificity for resectability was 90% and 86%, respectively. CT scan showed lower sensitivity than EUS for nodal staging (24% vs. 58%) and vascular invasion (58% vs. 86%); however, the specificities for nodal staging (88% vs. 85%) and vascular invasion (95% vs. 93%) were comparable in studies where both imaging techniques were performed. The sensitivity and specificity of CT in determining resectability (90% and 69%) was similar to that of EUS (87% and 89%). **Conclusions** EUS is an accurate pre-operative tool in the assessment of nodal staging, vascular invasion and resectability in patients with pancreatic cancer.

### INTRODUCTION

Endoscopic ultrasound (EUS) is frequently used in making the cytological diagnosis of pancreatic cancer; however, its role in the pre-operative staging of such patients is not entirely clear [1, 2]. Data on the performance characteristics of EUS utilizing the electronic curvilinear array echo endoscope and its relative advantage if any over dual-phase computed tomography (CT) in the pre-operative assessment of pancreatic cancer is limited [2, 3].

Pancreatic cancer is the fourth most common cancer in the United States and one of the leading causes of cancer-related mortality [4]. It has a poor 5-year survival rate of 4%, which has remained largely unchanged over the past 20 years [5]. This is primarily because the majority of patients with pancreatic adenocarcinoma progress to either metastatic or locally advanced disease in the asymptomatic phase. Surgical excision is the ultimate treatment with a 5-year survival rate after resection around 20% [3]. In recent studies, neoadjuvant chemoradiation has revealed promising results in patients with locally advanced disease [6].

As treatment of pancreatic cancer continues to evolve, accurate staging becomes increasingly important. The challenge for preoperative imaging studies is to accurately stage pancreatic cancer and determine resectability, hence avoiding unnecessary laparotomies in patients with locally advanced disease and directing them for

Received March 9<sup>th</sup>, 2013 – Accepted June 5<sup>th</sup>, 2013

**Key words** Endosonography; Neoplasm Staging; Pancreatic Neoplasms; Sensitivity and Specificity; Tomography, X-Ray Computed

**Correspondence** Haq Nawaz

Division of Gastroenterology, Hepatology and Nutrition; Presbyterian University Hospital, M2, C Wing; 200 Lothrop St. Pittsburgh, PA 15213; USA  
Phone: +1-412.979.0466; Fax: +1-412-648-9378  
E-mail: nawazh@upmc.edu

neoadjuvant chemoradiation. This approach may offer an opportunity for surgical cure in a select group of patients with loco-regional disease [7].

This is not an easy task; a recent study showed that complete resection with negative margins could only be achieved in 50% of patients with suspected loco-regional disease on routine imaging [8]. Recent advances in imaging technology including EUS and CT have shown promise in assessing loco-regional and distant spread of the tumor and improving prediction of resectability [2]. Currently, EUS is widely utilized in such patients, but there is no consensus on the role of EUS in the pre-operative imaging assessment of pancreatic cancer.

The primary aim of this meta-analysis is to review published literature to assess the accuracy and performance characteristics of pre-operative EUS in determining nodal staging (NS), vascular invasion (VI), and prediction of resectability (R) for pancreatic adenocarcinoma using surgery as the gold standard. A secondary aim is the head-to-head comparison of the accuracy of EUS vs. CT scan in studies that assessed both imaging modalities.

## METHODS

We used the PRISMA statement for quality assessment in reporting meta-analysis [9] (Supplementary Table [70]).

### Inclusion and Exclusion Criteria

The focus of this meta-analysis was on nodal staging, vascular invasion, and/or resectability of pancreatic adenocarcinoma. Studies solely on tumors with other histologic sub-types and ampullary tumors were excluded. In studies where data were heterogeneous every effort was made to dissect data for pancreatic adenocarcinoma.

EUS studies in which nodal staging, vascular invasion, and/or resectability was confirmed by surgery or clinical follow-up were selected. Only studies from which a 2x2 table could be constructed (i.e., actual counts for the number of false positive, false negative, true positive, and true negative was available) for any of the following: nodal staging, vascular invasion, and/or resectability, were included in the analysis. Abstracts and articles published in languages other than English were excluded. In case of studies from same authors with overlapping time periods of investigation only the larger study (greater number of patients) was considered in the analysis to avoid duplication of results.

EUS criteria used for lymph node involvement included: round shape, hypoechogenicity, smooth borders, and short axis size greater than 5 mm in most studies [10, 11]. EUS criteria used for vascular invasion included [12]: peripancreatic collateral

vessels around a pancreatic mass with obliteration of the normal anatomic location of one of the major adjacent vessel, tumor within vessel lumen, distortion of vessel contour, and loss of hyperechoic interface between the vessel and the tumor.

An independent review of all studies assessing CT scan in preoperative staging of pancreatic adenocarcinoma was not performed. However, in EUS studies with available CT data, a sub-analysis was performed to compare the accuracy of EUS and CT in predicting nodal staging, vascular invasion, and/or resectability.

### Study Identification

Two authors (H.N. and G.I.P.) independently conducted search for studies using the MEDLINE and Embase data base using the following search terms: "pancreatic carcinoma", "pancreatic cancer", "vascular invasion", "resectability", "TNM staging", "endoscopic ultrasound", "endoluminal ultrasound" and "EUS". "Related articles" for the articles selected using the initial strategy were also searched in MEDLINE. The last search was performed in May 2013. The reference list of citations in the shortlisted articles was reviewed to identify additional papers pertaining to the current study.

### Data Extraction

Data pertaining to calculation of sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for nodal staging, vascular invasion and resectability was extracted from individual studies by H.N. and G.I.P and differences were resolved by discussion. In cases of sufficient doubt we communicated with authors of individual studies to obtain additional data for clarification. The data was recorded on piloted forms and then transferred to a spread sheet in Microsoft Excel. Additional data that was recorded included name of first author, study duration, year of publication, type of study (retrospective vs. prospective), location of tumor (pancreatic vs. ampullary), histologic sub-types of tumors if reported, name of journal and type of EUS (radial vs. linear).

### Criteria Used to Assess Study Quality


Study quality was assessed using the following seven criteria as described by Dewitt *et al.* [2]. One point was given for each criterion that was fulfilled by an individual study: 1) consecutive series of patients to minimize selection bias; 2) sufficient description or standardization of EUS and CT to enable replication of technique; 3) independent or blind interpretation of both tests; 4) unbiased determination of resectability (0.5 point was given if decision for resectability was independent of either EUS or CT scan); 5) independent or blind

**Table 1.** Characteristics of studies included in the meta-analysis.

| Author                | Year of publication | No. of patients | Type of echo endoscope <sup>a</sup>  |
|-----------------------|---------------------|-----------------|--------------------------------------|
| Yasuda [39]           | 1988                | 42              | GF-UM2                               |
| Tio [41]              | 1990                | 43              | EU-M2, EU-M3, VU-M2, XMP-02          |
| Rosch [38]            | 1992                | 46              | GF-UM3, VM-UM2, JF-UM3               |
| Palazzo [11]          | 1993                | 64              | GF-UM2, GF-UM3                       |
| Yasuda [40]           | 1993                | 29              | GF-UM2, GF-UM3                       |
| Snady [42]            | 1994                | 38              | GF-UM2                               |
| Muller [43]           | 1994                | 16              | GF-UM3, GF-UM20                      |
| Chang [44]            | 1997                | 44              | GF-UM3, GF-UM20, FG-32UA             |
| Akahoshi [45]         | 1998                | 37              | GF-UM2,GF-UM3, GF-UM20               |
| Legmann [46]          | 1998                | 22              | GF-UM 20                             |
| Gress [47]            | 1999                | 81              | EU-M20, FG-32UA                      |
| Buscail [48]          | 1999                | 73              | EU-M3, EU-M20                        |
| Midwinter [10]        | 1999                | 34              | GF-UM20                              |
| Harrison [49]         | 1999                | 19              | GF-UM20                              |
| Rosch [50]            | 2000                | 75              | GF-UM3, UM-20                        |
| Ahmad [51]            | 2000                | 89              | GF-UM20                              |
| Mertz [52]            | 2000                | 16              | FG-32UA                              |
| Yusoff [53]           | 2003                | 45              | GF-UM3, GF-UM20, GF-UM130            |
| DeWitt [8]            | 2004                | 80              | GF-UM130, FG-36UX                    |
| Ramsay [54]           | 2004                | 27              | GF-UM3, GF-UM20, GF-UM 130           |
| Soriano [55]          | 2004                | 62              | GF-UM20                              |
| Latronico [56]        | 2005                | 34              | FG-36 UX                             |
| Aslanian [57]         | 2005                | 68              | GF-UM20, GF-UM130, GF-UC30P          |
| Fritscher-Ravens [58] | 2005                | 22              | FG-32UA, FG-34UX, EUB 8000, EUB 6000 |
| Kala [59]             | 2007                | 86              | EU-M30, GF-UM20/GIF-1T-140, UM-R3    |
| Virtue [60]           | 2008                | 33              | EG3630                               |
| Seicean [61]          | 2008                | 30              | GF-UM160                             |
| Morris-Stiff [63]     | 2011                | 25              | GF-UM20, UM-2000                     |
| Tellez-Avila [62]     | 2012                | 50              | GF-UCT140                            |
| <b>Total</b>          | -                   | <b>1,330</b>    | -                                    |

<sup>a</sup> **Radial scopes:** Olympus GF-UM2, GF-UM3, VU-M2, VM-UM2, JF-UM3, GF-UM20, GF-UM130, EU-M3, EU-M20, EU-M30, UM-R3, GF-UM160, XMP-02. **Linear scopes:** Pentax FG-32UA, FG-36UX, FG-35UX; Olympus GF-UC30P; Hitachi EUB 8000, EUB 6000

comparison with reference standard (surgical pathology); 6) report of operating characteristics such as sensitivity, specificity, PPV and NPV or description of sufficient data to enable calculation of same; and 7) clinical follow up in cases which were managed non-operatively to confirm diagnosis of pancreas cancer.



**Figure 1.** Flowchart of studies considered for inclusion in the meta-analysis.

## STATISTICS

The main performance measures in this study were sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values. For evaluating the heterogeneity among studies, Q statistic and I-square statistic were used [13]. Considering the correlation between paired outcomes and the heterogeneity, a bivariate generalized linear random effects model with logit link was utilized for EUS and CT scan on nodal staging, vascular invasion and/or resectability [14, 15]. This model estimated the pooled summary of each outcome, its standard error, and 95% confidence interval. The diagnostic performance of the sensitivity and specificity across studies was measured by the summary receiver operating characteristic curve (SROC), which incorporated with the covariance of paired outcomes [16]. The area under the curve (AUC) was used as a summary for the diagnostic accuracy.

**Table 2.** Criteria used to assess study quality.

| Studies               | Consecutive series | Standardized EUS/CT technique | Independent interpretation of both tests | Unbiased determination of resectability | Independent blind comparison with reference standard | Operating characteristics included | Clinical follow-up | Total quality score |
|-----------------------|--------------------|-------------------------------|--|---|--|------------------------------------|--------------------|---------------------|
| Yasuda [39]           | No                 | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Not applicable     | 3 of 5              |
| Tio [41]              | No                 | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Not applicable     | 3 of 5              |
| Rosch [38]            | Yes                | Yes                           | Yes                                      | No (0.5) <sup>b</sup>                   | Yes (<2 week)  | Yes                                | Not applicable     | 5.5 of 6            |
| Palazzo [11]          | Yes                | Yes                           | Yes                                      | No (0.5) <sup>b</sup>                   | Yes  | Yes                                | Yes                | 6.5 of 7            |
| Yasuda [40]           | No                 | No                            | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 2 of 6              |
| Snady [42]            | No                 | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Yes                | 4 of 6              |
| Muller [43]           | Yes                | Yes                           | Yes                                      | No                                      | Yes (<2 week)  | Yes                                | Yes                | 6 of 7              |
| Chang [44]            | Yes                | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Yes                | 5 of 6              |
| Akahoshi [45]         | Yes                | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Yes                | 5 of 6              |
| Legmann [46]          | No                 | Yes                           | Yes                                      | No                                      | Yes (<4 week)  | Yes                                | Not applicable     | 4 of 6              |
| Gress [47]            | Yes                | No                            | Yes                                      | No (0.5) <sup>b</sup>                   | Yes  | Yes                                | Not applicable     | 4.5 of 6            |
| Buscail [48]          | No                 | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Not applicable     | 3 of 5              |
| Midwinter [10]        | Yes                | Yes                           | Yes                                      | No                                      | Yes <sup>c</sup>                                     | Yes                                | Not applicable     | 5 of 6              |
| Harrison [49]         | No                 | No (0.5) <sup>a</sup>         | No                                       | No                                      | Yes (<30 days)                                       | Yes                                | Not applicable     | 3 of 6              |
| Rosch [50]            | No                 | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Yes                | 4 of 6              |
| Ahmad [51]            | No                 | No                            | Not applicable                           | No                                      | Yes  | Yes                                | Not applicable     | 2 of 5              |
| Mertz [52]            | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Yes                | 4 of 7              |
| Yusoff [53]           | Yes                | Yes                           | Not applicable                           | No                                      | Yes (<4 week)  | Yes                                | Not applicable     | 4 of 5              |
| DeWitt [8]            | Yes                | Yes                           | Yes                                      | No                                      | Yes (<3 week)  | Yes                                | Yes                | 6 of 7              |
| Ramsay [54]           | Yes                | Yes                           | Yes                                      | No                                      | Yes  | Yes                                | No                 | 5 of 7              |
| Soriano [55]          | Yes                | Yes                           | Yes                                      | No                                      | Yes (<2 week)  | Yes                                | No                 | 5 of 7              |
| Latronico [56]        | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Yes                | 4 of 7              |
| Aslanian [57]         | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 3 of 6              |
| Fritscher-Ravens [58] | Yes                | Yes                           | Not applicable                           | No                                      | Yes  | Yes                                | Not applicable     | 4 of 5              |
| Kala [59]             | No                 | No                            | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 2 of 6              |
| Virtue [60]           | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 3 of 6              |
| Seicean [61]          | No                 | Yes                           | No                                       | No (0.5) <sup>b</sup>                   | Yes (<2 week)  | Yes                                | Not applicable     | 3.5 of 6            |
| Morris-Stiff [63]     | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 3 of 6              |
| Tellez-Avila [62]     | No                 | Yes                           | No                                       | No                                      | Yes  | Yes                                | Not applicable     | 3 of 6              |

<sup>a</sup> Standardized for EUS but not for CT: one-half point given

<sup>b</sup> EUS findings were not used to select patients for surgery: one-half point given

<sup>c</sup> The time elapsed between EUS and CT to surgery was 56 and 57 days, respectively


We evaluated for small study effects by using Deek's funnel plot asymmetry test [17]. A sensitivity analysis, where each study is removed from the analysis and a separate pooled estimate is calculated, was carried out to assess the influence of each individual study on outcomes. All the analyses were conducted using STATA Version 12 (StataCorp LP, College Station, TX, USA). A two-tailed P value less than 0.05 was considered statistically significant except for Deek's funnel plot asymmetry test where significance level was chosen at P<0.10.

**RESULTS**

A total of 49 studies were considered for inclusion. The manuscripts of shortlisted articles were retrieved and assessed. Twenty studies were excluded [18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37] and 29 were

included in the analysis based on the criteria mentioned above and summarized in Figure 1 [8, 10, 11, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63]. The first author, year of publication, number of patients included, and type of echo endoscope used for each of the 29 selected studies are presented in Table 1. Of these 29 studies, 12 studies reported performance data on CT as well.

In respect to classification of pancreatic cancer (i.e., pancreatic vs. ampullary and adenocarcinoma vs. other histologic sub-types) data solely on pancreatic adenocarcinoma were extracted from 9 studies [8, 11, 43, 44, 45, 47, 51, 52, 61]. Eleven studies included data on tumors of other histologic sub-types [10, 38, 42, 46, 49, 53, 54, 57, 58, 60, 63] and 5 studies included data on ampullary tumors [10, 48,



**Figure 2.** Forest plot of sensitivity and specificity for endoscopic ultrasound (EUS). NS: nodal staging; VI: vascular invasion; R: resectability

49, 55, 60]. In studies with heterogeneous data the number of patients with tumors of other histologic subtypes and ampullary tumors was relatively small (less than 10).


**Criteria Used to Assess Study Quality**

None of the studies met all the criteria used to assess study quality as described in Table 2. Twelve studies reported consecutive series of patients [8, 10, 11, 38, 43, 44, 45, 47, 53, 54, 55, 58], 5 studies did not report EUS or CT techniques in sufficient detail to be reproducible [40, 47, 49, 51, 59]. Nine studies reported independent or blind interpretation of both imaging modalities [8, 10, 11, 38, 43, 46, 47, 54, 55]. None of the studies reported unbiased determination of resectability with respect to both EUS and CT scan as reported in

Table 2. Only four studies reported unbiased determination of resectability with respect to EUS and therefore received 0.5 point [11, 38, 47, 61]. In all studies the gold standard for comparison was surgical pathology and all studies either reported the operating characteristics or data that could be used to calculate the operating characteristics. Nine studies reported details of clinical follow-up where applicable [8, 11, 42, 43, 44, 45, 50, 52, 56].

**Performance Characteristics of EUS in Assessment of Nodal Staging, Vascular Invasion and Resectability**

The primary aim of the meta-analysis was to assess the diagnostic performance of EUS in assessment of all three primary outcomes: nodal staging, vascular invasion and resectability. Of the 29 studies



**Figure 3.** Deek's funnel plot to assess for small study effects. This is a method used for detecting small study effects based on a linear regression of log odds ratios on inverse root of effective sample sizes. When no small study effect exists, the test of the non-zero slope coefficient has P value >0.1, as was shown in our study.

**Table 3.** Summary of pooled estimates and 95% CI for endoscopic ultrasound.

| Diagnostic measures | Nodal staging (16 studies; n=512) |        | Vascular invasion (25 studies; n=886) |        | Resectability (9 studies; n=377) |        |
|---------------------|-----------------------------------|--------|---------------------------------------|--------|----------------------------------|--------|
|                     | Pooled estimates                  | 95% CI | Pooled estimates                      | 95% CI | Pooled estimates                 | 95% CI |
| Sensitivity         | 69%                               | 51-82% | 85%                                   | 76-91% | 90%                              | 71-97% |
| Specificity         | 81%                               | 70-89% | 91%                                   | 85-94% | 86%                              | 63-96% |
| PPV                 | 81%                               | 72-88% | 87%                                   | 81-92% | 85%                              | 66-94% |
| NPV                 | 65%                               | 56-73% | 87%                                   | 81-92% | 90%                              | 78-96% |
| AUC                 | 83%                               | 79-86% | 94%                                   | 92-96% | 95%                              | 92-96% |

included in this analysis, 16 studies examined nodal staging [10, 11, 38, 41, 43, 44, 45, 47, 49, 51, 53, 54, 56, 61, 63] for a total number of 512 patients, 25 examined vascular invasion [8, 10, 11, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 61, 62] for a total number of 886 patients, and 9 examined resectability [8, 46, 47, 48, 53, 54, 55, 59, 60] for a total number of 377 patients. There was moderate to high degree of heterogeneity in the studies for each of the conditions as is evident in the forest plots in Figure 2. The tests of heterogeneity were all highly significant with I<sup>2</sup> values ranging from 57.8 to 89.6. Because of the moderate to high degree of heterogeneity we used the random effects model for pooled estimates. Our sensitivity analysis indicated that no single study resulted in a substantial change

in the pooled estimates. The Deek's funnel plot asymmetry test failed to demonstrate a small study effect (Figure 3).

The pooled summary estimates for EUS nodal staging were: 69% (95% CI: 51-82%) for sensitivity; 81% (95% CI: 70-89%) for specificity; 81% (95% CI: 72-88%) for PPV; and 65% (95% CI: 56-73%) for NPV. The pooled summary estimates for vascular invasion were: sensitivity of 85% (95% CI: 76-91%); specificity of 91% (95% CI: 85-94%); PPV and NPV of 87% (95% CI: 81-92%) for both. The pooled estimates for resectability were: sensitivity of 90% (95% CI: 71-97%); specificity of 86% (95% CI: 63-96%); PPV of 85% (95% CI: 66-94%); and NPV of 90% (95% CI: 78-96%) (Figure 2 and Table 3).

**Table 4.** Diagnostic performance of studies employing linear echo endoscope.

| Authors, year of publication | No. of patients | Nodal staging |             |             | Vascular invasion |             |             | Resectability |             |             |
|------------------------------|-----------------|---------------|-------------|-------------|-------------------|-------------|-------------|---------------|-------------|-------------|
|                              |                 | Accuracy      | Sensitivity | Specificity | Accuracy          | Sensitivity | Specificity | Accuracy      | Sensitivity | Specificity |
| Gress, 1999 [47]             | 81              | 72%           | 82%         | 60%         | 93%               | 91%         | 96%         | 93%           | 95%         | 92%         |
| Mertz, 2000 [52]             | 16              | -             | -           | -           | 100%              | 100%        | 100%        | -             | -           | -           |
| DeWitt, 2004 [8]             | 80              | 44%           | -           | -           | 90%               | 88%         | 90%         | 77%           | 88%         | 68%         |
| Latronico, 2005 [56]         | 34              | 100%          | 100%        | 100%        | 97%               | 100%        | 94%         | -             | -           | -           |
| Aslanian, 2005 [57]          | 68              | -             | -           | -           | 63%               | 63%         | 64%         | -             | -           | -           |
| Fritscher-Ravens, 2005 [58]  | 22              | -             | -           | -           | 77%               | 86%         | 73%         | -             | -           | -           |
| Virtue, 2008 [60]            | 33              | -             | -           | -           | -                 | -           | -           | 73%           | 100%        | 40%         |
| Tellez-Avila, 2012 [62]      | 50              | -             | -           | -           | -                 | 62%         | 91%         | -             | -           | -           |

**Table 5.** Summary of pooled estimates and 95% CI for studies with both computed tomography (CT) and endoscopic ultrasound (EUS).

| Diagnostic measures | Nodal staging             |        | Vascular invasion          |        | Resectability             |        |
|---------------------|---------------------------|--------|----------------------------|--------|---------------------------|--------|
|                     | Pooled estimates          | 95% CI | Pooled estimates           | 95% CI | Pooled estimates          | 95% CI |
| <b>EUS</b>          | <b>(8 studies; n=281)</b> |        | <b>(12 studies; n=441)</b> |        | <b>(6 studies; n=250)</b> |        |
| Sensitivity         | 58%                       | 44-70% | 86%                        | 70-94% | 87%                       | 63-96% |
| Specificity         | 85%                       | 73-92% | 93%                        | 88-96% | 89%                       | 63-97% |
| PPV                 | 81%                       | 68-89% | 88%                        | 82-92% | 86%                       | 63-95% |
| NPV                 | 64%                       | 56-71% | 90%                        | 82-94% | 88%                       | 75-95% |
| AUC                 | 79%                       | 75-82% | 95%                        | 93-97% | 94%                       | 92-96% |
| <b>CT</b>           | <b>(8 studies; n=272)</b> |        | <b>(12 studies; n=431)</b> |        | <b>(6 studies; n=280)</b> |        |
| Sensitivity         | 24%                       | 16-34% | 58%                        | 45-69% | 90%                       | 77-96% |
| Specificity         | 88%                       | 77-94% | 95%                        | 89-98% | 69%                       | 41-87% |
| PPV                 | 67%                       | 52-79% | 90%                        | 78-95% | 72%                       | 53-85% |
| NPV                 | 51%                       | 43-59% | 75%                        | 69-81% | 87%                       | 78-93% |
| AUC                 | 51%                       | 47-56% | 91%                        | 88-93% | 90%                       | 87-92% |

A sub analysis on studies that utilized curvilinear echo endoscopes was also performed. From the original 29 studies, only 8 studies used linear EUS, either alone or in combination with radial EUS (total of 384 patients) [8, 47, 52, 56, 57, 58, 60, 62]. Since data were not presented in various studies, as well as the data available were heterogeneous because the authors of most of the studies did not use linear EUS in isolation and often they used radial EUS in combination with linear EUS (therefore, data for linear EUS could not be extracted), pooled statistics could not be performed for this subgroup. Results are as presented in Table 4.


**Performance Characteristics of EUS and CT in Assessment of Nodal Staging, Vascular Invasion and Resectability**

A comparison of EUS and CT was performed using data from 12 studies that assessed both imaging techniques as shown in Table 5. Eight studies [10, 11, 38, 43, 47, 54, 55, 63] assessed for nodal staging, 12 studies [8, 10, 11, 38, 43, 46, 47, 52, 54, 55, 56, 62] for vascular invasion, and 6 studies [8, 46, 47, 54, 55, 59] for resectability. CT scan showed lower

sensitivities for nodal staging (24%, 95% CI: 16-34%) and vascular invasion (58%, 95% CI 45-69%) when compared to EUS (nodal staging 58%, 95% CI: 44-70%; vascular invasion 86%, 95% CI: 70-94%). The sensitivity of CT for resectability (90%; 95% CI: 77-96%) was comparable to EUS (87%; 95% CI: 63-96%).

Following an exploratory data analysis approach by examining SROC curves (Figure 4), the AUCs of CT scan appear to be lower for nodal staging (51%, 95% CI: 47-56%) when compared to EUS nodal staging (79%, 95% CI: 75-82%). However AUCs for CT vascular invasion (91%, 95% CI: 88-93%) and resectability (90%, 95% CI: 87-92%) were comparable to EUS vascular invasion (95%, 95% CI: 93-97%), and resectability (94%, 95% CI: 92-96%). Further the AUC CIs for EUS and CT do not overlap. This can be regarded as a conservative test of hypothesis so we can conclude that EUS performs better than CT based on the available data.

A sub-analysis comparing EUS and CT scan in assessing venous and arterial invasion was also performed. Of the 12 studies with EUS and CT data, only 5 provided separate data on venous and



**Figure 4.** SROC in studies with both CT and EUS in assessing: a. nodal staging (NS); b. vascular invasion (VI); and c. resectability (R).



arterial invasion rather than pooling this information together as vascular invasion [10, 38, 59, 61, 62]. Due to the small number of studies with available data, pooled statistics could not be performed. The results of these studies are presented in Table 6.

**DISCUSSION**

Accurate pre-operative staging of pancreatic cancer is important in directing patients with resectable disease to surgery and to avoid resection in those with more advanced disease. The role of EUS with FNA in making a tissue diagnosis in patients with a pancreatic mass is well established. However, the role of EUS in pre-operative staging of disease and its impact on management remains unclear. Prior studies have yielded conflicting results primarily due to small studies with heterogeneous patient populations. Any information gleaned from older studies may not be applicable today due to improvements in computed tomography and EUS, with the universal use of linear array scopes for pancreatic disease.

In this meta-analysis, all EUS data in pre-operative staging of pancreatic cancer available to date were extracted using strict inclusion criteria, so as to provide summary estimates on the performance of EUS in assessing nodal staging, vascular invasion, and/or resectability. When compared to the study by DeWitt *et al.* [2], which was a systematic review of literature in this field without pooled statistics, our study reported pooled statistics using the random effects model to account for moderate to high degree of heterogeneity in the data collected. When compared to the meta-analysis by Puli *et al.* [3], which was limited to EUS staging of vascular invasion in pancreatic and ampullary tumors, our study reported pooled statistics for all three pertinent outcomes in the pre-operative imaging assessment of pancreatic adenocarcinoma including nodal staging, vascular invasion, and resectability.

In addition, we performed a sub-group analysis directly comparing EUS with CT scan in studies that reported results for both modalities. Our results are in concordance with Puli *et al.* [3], but in addition demonstrate that EUS is accurate in the assessment of nodal staging and resectability.

In our analysis, EUS was found to perform with high accuracy in all three domains including nodal staging, vascular invasion, and resectability. Since current practice in expert centers is the use of linear echo endoscopes when assessing patients with suspected pancreatic cancer for both tissue sampling and staging purposes we attempted to perform a sub-analysis using only linear EUS data. However, data on linear EUS was limited precluding the performance of summary statistics.

The accuracy of EUS for detecting lymph node metastasis in the selected studies ranged from 44 to 100% with a pooled sensitivity of 69% and specificity of 81%. The pooled sensitivity was rather low and this could be explained by peri-tumoral inflammation and/or large tumor size, which may potentially hinder detection of lymphadenopathy [64]. EUS-FNA in addition to diagnostic EUS has the potential to increase the sensitivity of nodal staging. One study reported sensitivity of 82% when EUS-FNA was used to confirm malignant lymphadenopathy [65].

At present, loco-regional lymphadenopathy does not preclude surgical intervention, especially for tumors involving the pancreatic head, since these can be removed en bloc with the tumor [61, 65]. In contrast, involvement of celiac lymph nodes portends an unresectable state and careful survey of this region is therefore warranted [61]. The accuracy of CT for lymph node staging ranged from 38 to 77% with a pooled sensitivity of 24% and specificity of 88%. Based on our head-to-head comparison, EUS was more sensitive and accurate in detecting malignant lymph nodes.

**Table 6.** Comparison of endoscopic ultrasound (EUS) vs. computed tomography (CT) in assessing arterial and venous invasion.

| Authors, year of publication | No. of patients | Arterial invasion |             |             | Venous invasion |             |             |
|------------------------------|-----------------|-------------------|-------------|-------------|-----------------|-------------|-------------|
|                              |                 | Accuracy          | Sensitivity | Specificity | Accuracy        | Sensitivity | Specificity |
| <b>EUS</b>                   |                 |                   |             |             |                 |             |             |
| Rosch, 1992 [38]             | 46              | 77%               | -           | -           | 77%             | 91%         | 97%         |
| Midwinter, 1999 [10]         | 34              | -                 | 17%         | 67%         | -               | 81%         | 86%         |
| Kala, 2007 [59]              | 86              | 15%               | -           | -           | 17%             | -           | -           |
| Seicean, 2008 [61]           | 30              | 87%               | -           | -           | 80%             | -           | -           |
| Tellez-Avila, 2012 [62]      | 50              | -                 | 67%         | 100%        | -               | 80%         | 88%         |
| <b>CT</b>                    |                 |                   |             |             |                 |             |             |
| Rosch, 1992 [38]             | 46              | 83%               | -           | -           | 83%             | 36%         | 85%         |
| Midwinter, 1999 [10]         | 34              | -                 | 50%         | 100%        | -               | 56%         | 100%        |
| Kala, 2007 [59]              | 86              | 2%                | -           | -           | 4%              | -           | -           |
| Seicean, 2008 [61]           | 30              | -                 | -           | -           | -               | -           | -           |
| Tellez-Avila, 2012 [62]      | 50              | -                 | 67%         | 90%         | -               | 30%         | 90%         |



Current practice in expert centers has evolved to surgical excision of pancreatic adenocarcinoma with venous invasion accompanied by venous reconstruction [3]. Furthermore, recent studies support the use of neoadjuvant chemoradiation in locally advanced disease with arterial vascular invasion [66]. Therefore, accurate assessment of vascular invasion is critical for avoiding unneeded laparotomies and guide initial treatment. CT scan, which has been traditionally considered the mainstream pre-operative staging tool, can be falsely negative for vascular invasion in about 20% of patients [12].

In our analysis, EUS accuracy in the detection for vascular invasion ranged between 62 to 100% with a pooled sensitivity of 85% and specificity of 91%. In a previous meta-analysis by Puli *et al.* [3], EUS revealed a sensitivity of 73% (95% CI: 69-77%) and specificity of 91% (95% CI: 88-92%) in diagnosing vascular invasion. The higher sensitivity seen in our analysis could be explained by the inclusion of additional studies [61, 62] with high sensitivity and the exclusion of ampullary cancer data, which could have increased the homogeneity of our study population. The accuracy of CT for diagnosis of vascular invasion ranged from 62 to 95% with a pooled sensitivity of 58% and specificity of 95%. Based on our head-to-head comparison, EUS appeared to be more sensitive in detecting vascular invasion when compared to CT scan. Both CT and EUS revealed comparable specificities.

Four different EUS criteria have been used in studies to define vascular invasion. Peripancreatic venous collaterals and tumor within vessel lumen are usually straightforward, easy to document with a high specificity [12]. However, they are less prevalent and less sensitive when compared to abnormal vessel contour and loss of the vessel-pancreatic interface. Furthermore, the diagnostic accuracy may differ among different vessels; the superior mesenteric vein is long considered the most difficult to image [3]. It is noteworthy that criteria for arterial invasion have not been standardized [12]. Whereas arterial involvement is obvious in cases of vessel wall irregularity or stenosis, loss of hyperechoic interface may not be considered an absolute contraindication for surgical resection in some centers [12].

EUS has been suggested to be more sensitive in detecting venous invasion, whereas CT is considered more sensitive in detecting arterial invasion in the pre-operative staging of patients with pancreatic cancer [10, 35, 38, 59]. Since current management in expert centers differs in locally advanced pancreatic cancer with venous and arterial invasion, we attempted to perform a subgroup comparison between EUS and CT scan in

assessing venous vs. arterial invasion. Only scarce comparative data were reported especially for arterial invasion, which precluded the performance of summary statistics. It appeared though that EUS and CT scan perform similarly in assessing venous invasion and CT scan may be superior in assessing arterial invasion.

The accuracy of EUS for detecting resectability in our analysis ranged between 62 to 94% with a pooled sensitivity of 90% and specificity of 86%. The accuracy of CT scan ranged from 60 to 92% with a pooled sensitivity of 90% and specificity of 69%. Based on our head-to-head comparison, EUS and CT scan performed similarly in predicting resectability. It is important to mention that resectability largely depends on surgical practices. Some surgeons resect almost any pancreatic tumor, including performing vascular reconstruction for venous invasion, while others operate only in very early stages of loco-regional cancers referring the rest of the patients to neoadjuvant chemoradiation [12].

In addition to EUS and CT MRI has emerged as a complementary imaging modality for staging of pancreas cancer [36, 43]. Soriano *et al.* showed that for N-staging MRI had a lower sensitivity (15%) but higher specificity (93%) when compared with EUS (36% and 87%, respectively) and CT (37% and 79%, respectively). For vascular invasion MRI had sensitivity of 59% and specificity of 84% in comparison to EUS (42% and 97%, respectively) and CT (67% and 94%, respectively) [55]. In a meta-analysis published in 2005 comparing prediction of resectability between MRI and helical CT, the sensitivity was comparable at 82% vs. 81% and the specificity was 78% vs. 82%, respectively [67]. Other studies have shown that MRI may be superior than CT in detecting liver metastasis and peritoneal implants [68, 69]. Pooled estimates comparing MRI with EUS and CT could not be performed in our study due to small number of studies (n=3) providing operating characteristics [43, 54, 55].

This meta-analysis has several limitations. First, a moderate to high degree of heterogeneity was found in the selected studies for each of the three primary outcomes. Despite efforts to extract data only on pancreatic adenocarcinoma some studies had a small proportion of patients with ampullary tumors and/or tumors with other histologic subtypes. Second, the selected studies were published in a wide time range from 1988 to 2012. During the last 25 years, EUS and CT scan technology has evolved. Thus, the technology used in the earlier studies likely does not reflect current practices. We attempted to focus our analysis on linear EUS; however, this subgroup analysis could not be

performed, because of scarce availability of data on current technology. Third, all studies were relatively small in size; none of the selected studies exceeded a sample size of 100 and only one third enrolled more than 50 patients. Finally, even though most of the included studies met majority criteria of quality assessment, the documentation of quality criteria was found to be suboptimal in a few studies.

In conclusion, this meta-analysis, despite its limitations, clearly showed that EUS is an accurate pre-operative tool in the assessment of nodal staging, vascular invasion and resectability in patients with pancreatic adenocarcinoma. On head-to-head comparison, EUS appeared to perform better than CT scan in respect to nodal staging. Based on these results, we conclude that EUS staging should be the standard of care along with state-of-the-art CT scan for the preoperative evaluation of patients with pancreatic cancer. However, large, prospective, multicenter studies that will directly compare the accuracy of linear EUS vs. new generation CT scanners are still needed.

---

**Funding Sources** The project described was supported by the National Institutes of Health through grant numbers UL1RR024153 and UL1TR000005

**Conflict of interest** The authors do not have any conflict of interest to report

---

#### References

1. Rosch T, Lorenz R, Braig C, Dancygier H, Classen M. Endoscopic ultrasound in small pancreatic tumors. *Z Gastroenterol* 1991; 29(3):110-5. [PMID: 2058229]
2. DeWitt J, Devereaux BM, Lehman GA, Sherman S, Imperiale TF. Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of pancreatic cancer: a systematic review. *Clin Gastroenterol Hepatol* 2006; 4(6):717-25. [PMID: 16675307]
3. Puli SR, Singh S, Hagedorn CH, Reddy J, Olyae M. Diagnostic accuracy of EUS for vascular invasion in pancreatic and periampullary cancers: a meta-analysis and systematic review. *Gastrointest Endosc* 2007; 65(6):788-97. [PMID: 17350008]
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. *CA Cancer J Clin* 2010; 60(5):277-300. [PMID: 20610543]
5. Je E. The burden of digestive diseases in the United States. In: US Department of Health and Human Services NIOH, National Institute of Diabetes and Digestive and Kidney Diseases., ed. Washington DC: US Government Printing Office, 2008.
6. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. *Cancer* 2011; 11:2044-9. [PMID: 21523715]
7. DiMagna EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. *American Gastroenterological Association. Gastroenterology* 1999; 117(6):1464-84. [PMID: 10579989]

8. DeWitt J, Devereaux B, Chriswell M, McGreevy K, Howard T, Imperiale TF, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. *Ann Intern Med* 2004; 141(10):753-63. [PMID: 15545675]
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009; 62(10):e1-34. [PMID: 19631507]
10. Midwinter MJ, Beveridge CJ, Wilsdon JB, Bennett MK, Baudouin CJ, Charnley RM. Correlation between spiral computed tomography, endoscopic ultrasonography and findings at operation in pancreatic and ampullary tumours. *Br J Surg* 1999; 86(2):189-93. [PMID: 10100785]
11. Palazzo L, Roseau G, Gayet B, Vilgrain V, Belghiti J, Fekete F, Paolaggi JA. Endoscopic ultrasonography in the diagnosis and staging of pancreatic adenocarcinoma. Results of a prospective study with comparison to ultrasonography and CT scan. *Endoscopy* 1993; 25(2):143-50. [PMID: 8491130]
12. Snady H. EUS criteria for vascular invasion: analyzing the meta-analysis. *Gastrointest Endosc* 2007; 65(6):798-807. [PMID: 17466198]
13. Cooper H VJ. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation, 2009.
14. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *J Clin Epidemiol* 2005; 58(10):982-90. [PMID: 16168343]
15. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. *J Clin Epidemiol* 2006; 59(12):1331-2. [PMID: 17098577]
16. Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. *Med Decis Making* 1993; 13(4):313-21. [PMID: 8246704]
17. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol* 2005; 58(9):882-93. [PMID: 16085191]
18. Yovino S, Darwin P, Daly B, Garofalo M, Moesinger R. Predicting unresectability in pancreatic cancer patients: the additive effects of CT and endoscopic ultrasound. *J Gastrointest Surg* 2007; 11(1):36-42. [PMID: 17390184]
19. Brugge WR, Lee MJ, Kelsey PB, Schapiro RH, Warshaw AL. The use of EUS to diagnose malignant portal venous system invasion by pancreatic cancer. *Gastrointest Endosc* 1996; 43(6):561-7. [PMID: 8781933]
20. Giovannini M, Seitz JF. Endoscopic ultrasonography with a linear-type echoendoscope in the evaluation of 94 patients with pancreatobiliary disease. *Endoscopy* 1994; 26(7):579-85. [PMID: 8001484]
21. Marty O, Aubertin JM, Bouillot JL, Hernigou A, Bloch F, Petite JP. Prospective comparison of ultrasound endoscopy and computed tomography in the assessment of locoregional invasiveness of malignant ampullar and pancreatic tumors verified surgically. *Gastroenterol Clin Biol* 1995; 19(2):197-203. [PMID: 7750710]
22. Howard TJ, Chin AC, Streib EW, Kopecky KK, Wiebke EA. Value of helical computed tomography, angiography, and endoscopic ultrasound in determining resectability of periampullary carcinoma. *Am J Surg* 1997; 174(3):237-41. [PMID: 9324129]
23. Gress F, Savides T, Cummings O, Sherman S, Lehman G, Zaidi S, Hawes R. Radial scanning and linear array endosonography for staging pancreatic cancer: a prospective randomized

- comparison. *Gastrointest Endosc* 1997; 45(2):138-42. [PMID: 9040998]
24. Cannon ME, Carpenter SL, Elta GH, Nostrant TT, Kochman ML, Ginsberg GG, et al. EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms. *Gastrointest Endosc* 1999; 50(1):27-33. [PMID: 10385718]
25. Shoup M, Hodul P, Aranha GV, Choe D, Olson M, Leya J, Losurdo J. Defining a role for endoscopic ultrasound in staging periampullary tumors. *Am J Surg* 2000; 179(6):453-6. [PMID: 11004329]
26. Ahmad NA, Kochman ML, Lewis JD, Kadish S, Morris JB, Rosato EF, Ginsberg GG. Endosonography is superior to angiography in the preoperative assessment of vascular involvement among patients with pancreatic carcinoma. *J Clin Gastroenterol* 2001; 32(1):54-8. [PMID: 11154172]
27. Tierney WM, Francis IR, Eckhauser F, Elta G, Nostrant TT, Scheiman JM. The accuracy of EUS and helical CT in the assessment of vascular invasion by peripapillary malignancy. *Gastrointest Endosc* 2001; 53(2):182-8. [PMID: 11174289]
28. Schwarz M, Pauls S, Sokiranski R, Brambs HJ, Glasbrenner B, Adler G, et al. Is a preoperative multidagnostic approach to predict surgical resectability of periampullary tumors still effective? *Am J Surg* 2001; 182(3):243-9. [PMID: 11587685]
29. Rivadeneira DE, Pochapin M, Grobmyer SR, Lieberman MD, Christos PJ, Jacobson I, Daly JM. Comparison of linear array endoscopic ultrasound and helical computed tomography for the staging of periampullary malignancies. *Ann Surg Oncol* 2003; 10(8):890-7. [PMID: 14527907]
30. Tian YT, Wang CF, Shan Y, Zhao DB, Wang GQ, Zhao XM, et al. Prospective evaluation of ultrasonography, multi-slice spiral CT, endoscopic ultrasonography, and magnetic resonance imaging in assessment of TNM staging and assessment of resectability in pancreatic carcinoma. *Zhonghua Yi Xue Za Zhi* 2008; 88(40):2829-32. [PMID: 19080491]
31. Tian YT, Wang CF, Wang GQ, Zhao XM, Ouyang H, Hao YZ, et al. Prospective evaluation of the clinical significance of ultrasonography, helical computed tomography, magnetic resonance imaging and endoscopic ultrasonography in the assessment of vascular invasion and lymph node metastasis of pancreatic carcinoma. *Zhonghua Zhong Liu Za Zhi* 2008; 30(9):682-5. [PMID: 19173910]
32. Tian YT, Wang CF, Zhao XM, Wang GQ, Ou YH, Hao YZ, et al. Prospective comparison of ultrasonography, helical computed tomography, magnetic resonance imaging, and endoscopic ultrasonography in assessing locoregional invasion of primary pancreatic carcinoma. *Zhonghua Zhong Liu Za Zhi* 2008; 30(4):270-3. [PMID: 18788630]
33. Ho JM, Eysselein VE, Stabile BE. The value of endoscopic ultrasonography in predicting resectability and margins of resection for periampullary tumors. *Am Surg* 2008; 74(10):1026-9. [PMID: 18942637]
34. Lu ZC, Guo JM, Zhang YL, Tian PL, Zhang L, Yu JP, Bao XY. Comparison of endoscopic ultrasonography with computer-assisted tomography in the determination of preoperative stage and resectability of pancreatic and ampullary cancers. *Zhonghua Zhong Liu Za Zhi* 2006; 28(6):441-4. [PMID: 17152491]
35. Mansfield SD, Scott J, Oppong K, Richardson DL, Sen G, Jaques BC, et al. Comparison of multislice computed tomography and endoscopic ultrasonography with operative and histological findings in suspected pancreatic and periampullary malignancy. *Br J Surg* 2008; 95(12):1512-20. [PMID: 18942059]
36. Shami VM, Mahajan A, Loch MM, Stella AC, Northup PG, White GE, et al. Comparison between endoscopic ultrasound and magnetic resonance imaging for the staging of pancreatic cancer. *Pancreas* 2011; 40(4):567-70. [PMID: 21499211]
37. Arabul M, Karakus F, Alper E, Kandemir A, Celik M, Karakus V, et al. Comparison of multidetector CT and endoscopic ultrasonography in malignant pancreatic mass lesions. *Hepatogastroenterology* 2012; 59(117):1599-603. [PMID: 22155849]
38. Rosch T, Braig C, Gain T, Feuerbach S, Siewert JR, Schusdziarra V, Classen M. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography. *Gastroenterology* 1992; 102(1):188-99. [PMID: 1727753]
39. Yasuda K, Mukai H, Fujimoto S, Nakajima M, Kawai K. The diagnosis of pancreatic cancer by endoscopic ultrasonography. *Gastrointest Endosc* 1988; 34(1):1-8. [PMID: 3280392]
40. Yasuda K, Mukai H, Nakajima M, Kawai K. Staging of pancreatic carcinoma by endoscopic ultrasonography. *Endoscopy* 1993; 25(2):151-5. [PMID: 8491131]
41. Tio TL, Tytgat GN, Cikot RJ, Houthoff HJ, Sars PR. Ampullopapillary carcinoma: preoperative TNM classification with endosonography. *Radiology* 1990; 175(2):455-61. [PMID: 2183284]
42. Snady H, Bruckner H, Siegel J, Cooperman A, Neff R, Kiefer L. Endoscopic ultrasonographic criteria of vascular invasion by potentially resectable pancreatic tumors. *Gastrointest Endosc* 1994; 40(3):326-33. [PMID: 8056236]
43. Muller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. *Radiology* 1994; 190(3):745-51. [PMID: 8115622]
44. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma. *Gastrointest Endosc* 1997; 45(5):387-93. [PMID: 9165320]
45. Akahoshi K, Chijiwa Y, Nakano I, Nawata H, Ogawa Y, Tanaka M, et al. Diagnosis and staging of pancreatic cancer by endoscopic ultrasound. *Br J Radiol* 1998; 71(845):492-6. [PMID: 9691893]
46. Legmann P, Vignaux O, Dousset B, Baraza AJ, Palazzo L, Dumontier I, et al. Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. *AJR Am J Roentgenol* 1998; 170(5):1315-22. [PMID: 9574609]
47. Gress FG, Hawes RH, Savides TJ, Ikenberry SO, Cummings O, Kopecky K, et al. Role of EUS in the preoperative staging of pancreatic cancer: a large single-center experience. *Gastrointest Endosc* 1999; 50(6):786-91. [PMID: 10570337]
48. Buscail L, Pages P, Berthelemy P, Fourtanier G, Frexinos J, Escourrou J. Role of EUS in the management of pancreatic and ampullary carcinoma: a prospective study assessing resectability and prognosis. *Gastrointest Endosc* 1999; 50(1):34-40. [PMID: 10385719]
49. Harrison JL, Millikan KW, Prinz RA, Zaidi S. Endoscopic ultrasound for diagnosis and staging of pancreatic tumors. *Am Surg* 1999; 65(7):659-64. [PMID: 10399976]
50. Rosch T, Dittler HJ, Strobel K, Meining A, Schusdziarra V, Lorenz R, et al. Endoscopic ultrasound criteria for vascular invasion in the staging of cancer of the head of the pancreas: a blind reevaluation of videotapes. *Gastrointest Endosc* 2000; 52(4):469-7. [PMID: 11023562]
51. Ahmad NA, Lewis JD, Ginsberg GG, Rosato EF, Morris JB, Kochman ML. EUS in preoperative staging of pancreatic cancer. *Gastrointest Endosc* 2000; 52(4):463-8. [PMID: 11023561]
52. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. *Gastrointest Endosc* 2000; 52(3):367-71. [PMID: 10968852]
53. Yusoff IF, Mendelson RM, Edmunds SE, Ramsay D, Cullingford GL, Fletcher DR, Zimmerman AM. Preoperative assessment of pancreatic malignancy using endoscopic ultrasound. *Abdom Imaging* 2003; 28(4):556-62. [PMID: 14580100]

54. Ramsay D, Marshall M, Song S, Zimmerman M, Edmunds S, Yusoff I, et al. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodium-enhanced magnetic resonance imaging. *Australas Radiol* 2004; 48(2):154-61. [PMID: 15230749]
55. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, et al. Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. *Am J Gastroenterol* 2004; 99(3):492-501. [PMID: 15056091]
56. Latronico A, Crosta C, De Fiori E, Carolei A, Ravizza D, Bellomi M. Endoscopic ultrasound and Computed Tomography in the diagnosis, locoregional staging and assessment of vascular infiltration of pancreatic carcinoma. *Radiol Med* 2005; 109(5-6):508-15. [PMID: 15973224]
57. Aslanian H, Salem R, Lee J, Andersen D, Robert M, Topazian M. EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histologic correlates. *Am J Gastroenterol* 2005; 100(6):1381-5. [PMID: 15929774]
58. Fritscher-Ravens A, Knoefel WT, Krause C, Swain CP, Brandt L, Patel K. Three-dimensional linear endoscopic ultrasound-feasibility of a novel technique applied for the detection of vessel involvement of pancreatic masses. *Am J Gastroenterol* 2005; 100(6):1296-302. [PMID: 15929760]
59. Kala Z, Valek V, Hlavsa J, Hana K, Vanova A. The role of CT and endoscopic ultrasound in pre-operative staging of pancreatic cancer. *Eur J Radiol* 2007; 62(2):166-9. [PMID: 17344007]
60. Virtue MA, Mallery S, Li R, Sielaff TD. Clinical utility of endoscopic ultrasound in solid pancreatic mass lesions deemed resectable by computer tomography. *JOP* 2008; 9(2):167-71. [PMID: 18326924]
61. Seicean A, Badea R, Mocan T, Iancu C, Pop T, Seicean R, et al. Radial endoscopic ultrasonography in the preoperative staging of pancreatic cancer. *J Gastrointest Liver Dis* 2008; 17(3):273-8. [PMID: 18836619]
62. Tellez-Avila FI, Chavez-Tapia NC, Lopez-Arce G, Franco-Guzman AM, Sosa-Lozano LA, Alfaro-Lara R, et al. Vascular invasion in pancreatic cancer: predictive values for endoscopic ultrasound and computed tomography imaging. *Pancreas* 2012; 41(4):636-8. [PMID: 22460727]
63. Morris-Stiff G, Escofet X, Barry JD, Lewis WG, Puntis MC, Roberts SA. Selective use of endoscopic ultrasound in the evaluation of carcinomas of the pancreatic head. *Digestive surgery* 2011; 28(5-6):373-8. [PMID: 22134196]
64. Nakaizumi A, Uehara H, Iishi H, Tatsuta M, Kitamura T, Kuroda C, et al. Endoscopic ultrasonography in diagnosis and staging of pancreatic cancer. *Dig Dis Sci* 1995; 40(3):696-700. [PMID: 7895567]
65. Shin HJ, Lahoti S, Sneige N. Endoscopic ultrasound-guided fine-needle aspiration in 179 cases: the M. D. Anderson Cancer Center experience. *Cancer* 2002; 96(3):174-80. [PMID: 12115306]
66. Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Bellanne G, et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. *J Am Coll Surg* 2005; 201(3):359-65. [PMID: 16125068]
67. Bipat S, Phoa SS, van Delden OM, Bossuyt PM, Gouma DJ, Lameris JS, Stoker J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. *J Comp Assist Tomogr* 2005; 29(4):438-45. [PMID: 16012297]
68. Martin DR, Semelka RC. MR imaging of pancreatic masses. *Magn Reson Imaging Clin N Am* 2000; 8(4):787-812. [PMID: 11149680]
69. Freeny PC. Pancreatic imaging. New modalities. *Gastroenterology Clin N Am* 1999; 28(3):723-46. [PMID: 10503147]
70. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med* 2009; 6(6):e1000097. [PMID: 19621072]
-

**Supplementary Table.** The PRISMA statement.

| Section/topic                      | #  | Checklist item  | Reported in the manuscript <sup>a</sup>   |
|------------------------------------|----|---|---|
| <b>TITLE</b>                       |    |   |   |
| Title                              | 1  | Identify the report as a systematic review, meta-analysis, or both.   | <b>The title identifies this paper as a meta-analysis. Page 484</b>   |
| <b>ABSTRACT</b>                    |    |   |   |
| Structured summary                 | 2  | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | <b>The abstract has been structured into background, objective, design, patients, intervention, main outcome measure, result and conclusion. This is in accordance with the manuscript preparation guidelines published in JOP. Journal of the Pancreas. Page 484</b> |
| <b>INTRODUCTION</b>                |    |   |   |
| Rationale                          | 3  | Describe the rationale for the review in the context of what is already known.  | <b>This has been described in the "Introduction". Pages 484-485</b>   |
| Objectives                         | 4  | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  | <b>This is provided in the last paragraph in the "Introduction". Page 485</b>   |
| <b>METHODS</b>                     |    |   |   |
| Protocol and registration          | 5  | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.   | <b>This is not applicable to our study</b>  |
| Eligibility criteria               | 6  | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  | <b>This has been described in the section "Inclusion and Exclusion Criteria". 485</b>   |
| Information sources                | 7  | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  | <b>This has been described in the section "Study Identification". Page 485</b>  |
| Search                             | 8  | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   | <b>This has been described in the section "Study Identification". Page 485</b>  |
| Study selection                    | 9  | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).   | <b>This has been described in the section "Inclusion and Exclusion Criteria". Page 485</b>  |
| Data collection process            | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  | <b>This has been described in the section "Data Extraction". Page 485</b>   |
| Data items                         | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.   | <b>This has been described in the section "Data Extraction". Page 485</b>   |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | <b>This has been described in the section "Criteria Used to Assess Study Quality". Pages 485-486</b>  |
| Summary measures                   | 13 | State the principal summary measures (e.g., risk ratio, difference in means).   | <b>This has been described in the section "Statistics". Pages 486-487</b>   |
| Synthesis of results               | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I <sup>2</sup> ) for each meta-analysis.  | <b>This has been described in the section "Statistics". Page 486-487</b>  |
| Risk of bias across studies        | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  | <b>This has been described in the section "Statistics". Page 486-487</b>  |
| Additional analyses                | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  | <b>This has been described in the section "Statistics". Page 486-487</b>  |

| <b>RESULTS</b>                |    |  |   |
|-------------------------------|----|--|---|
| Study selection               | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  | <b>This has been described in Figure 1</b>                      |
| Study characteristics         | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.   | <b>This has been described in Table 1</b>                       |
| Risk of bias within studies   | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  | <b>This has been described in "Results". Page 488</b>           |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | <b>This has been described in Table 3 and Figure 2</b>          |
| Synthesis of results          | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency.  | <b>This has been described in Table 3 and Table 5</b>           |
| Risk of bias across studies   | 22 | Present results of any assessment of risk of bias across studies (see Item 15).  | <b>This has been described in "Results". Page 488</b>           |
| Additional analysis           | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  | <b>This has been described in Pages 488-490</b>                 |
| <b>DISCUSSION</b>             |    |  |   |
| Summary of evidence           | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).                     | <b>This has been described in the discussion. Pages 491-492</b> |
| Limitations                   | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  | <b>This has been described in the discussion. Pages 492-493</b> |
| Conclusions                   | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research.  | <b>This has been described in the discussion. Page 493</b>      |
| <b>FUNDING</b>                |    |  |   |
| Funding                       | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.   | <b>This has been described in Page 493</b>                      |

From Moher *et al.* (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 [70]. For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org)

<sup>a</sup> Pages are numbered according to the .PDF version of the manuscript